Tolmar

In a research report published Friday morning, Goldman Sachs has lowered its EPS estimates for Impax Laboratories (NASDAQ: IPXL) to reflect the pharmaceutical company's supply agreement with Tolmar and changes in the Adderall XR market. According to Goldman Sachs, "While the impact from Actavis...